245 related articles for article (PubMed ID: 29896291)
1. Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy.
Kobayashi H; Naito T; Omae K; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Endo M; Harada H; Takahashi T
J Cancer; 2018; 9(11):2054-2060. PubMed ID: 29896291
[No Abstract] [Full Text] [Related]
2. The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.
Asai N; Katsuda E; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Yokoe N; Takahashi A; Yamaguchi E; Kubo A
Tumori; 2017 Jan; 103(1):60-65. PubMed ID: 27791236
[TBL] [Abstract][Full Text] [Related]
3. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.
Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239
[TBL] [Abstract][Full Text] [Related]
4. ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease.
Kobayashi H; Naito T; Omae K; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Endo M; Takahashi T
Lung Cancer; 2018 Jul; 121():48-53. PubMed ID: 29858026
[TBL] [Abstract][Full Text] [Related]
5. Glasgow Prognostic Score predicts chemotherapy-triggered acute exacerbation-interstitial lung disease in patients with non-small cell lung cancer.
Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
Thorac Cancer; 2021 Mar; 12(5):667-675. PubMed ID: 33480111
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.
Otsuka K; Nokihara H; Mitsuhashi A; Ozaki R; Yabuki Y; Yoneda H; Ogino H; Nishioka Y
Thorac Cancer; 2022 Nov; 13(21):2978-2984. PubMed ID: 36106507
[TBL] [Abstract][Full Text] [Related]
7. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis.
Izuka S; Yamashita H; Iba A; Takahashi Y; Kaneko H
Rheumatology (Oxford); 2021 May; 60(5):2348-2354. PubMed ID: 33241299
[TBL] [Abstract][Full Text] [Related]
8. Outcomes after lobar versus sublobar resection for clinical stage I non-small cell lung cancer in patients with interstitial lung disease.
Tsutani Y; Mimura T; Kai Y; Ito M; Misumi K; Miyata Y; Okada M
J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1089-1096.e1. PubMed ID: 28483268
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
Yıldırım F; Türk M; Bitik B; Erbaş G; Köktürk N; Haznedaroğlu Ş; Türktaş H
Kaohsiung J Med Sci; 2019 Jun; 35(6):365-372. PubMed ID: 30913371
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease.
Kato M; Shukuya T; Takahashi F; Mori K; Suina K; Asao T; Kanemaru R; Honma Y; Muraki K; Sugano K; Shibayama R; Koyama R; Shimada N; Takahashi K
BMC Cancer; 2014 Jul; 14():508. PubMed ID: 25012241
[TBL] [Abstract][Full Text] [Related]
11. Is operation safe for lung cancer patients with interstitial lung disease on computed tomography?
Tang H; Ren Y; She Y; Dai C; Wang T; Su H; Sun W; Jiang G; Chen C
Ther Adv Respir Dis; 2020; 14():1753466620971137. PubMed ID: 33167797
[TBL] [Abstract][Full Text] [Related]
12. Related factors, increased mortality and causes of death in patients with rheumatoid arthritis-associated interstitial lung disease.
Kakutani T; Hashimoto A; Tominaga A; Kodama K; Nogi S; Tsuno H; Ogihara H; Nunokawa T; Komiya A; Furukawa H; Tohma S; Matsui T
Mod Rheumatol; 2020 May; 30(3):458-464. PubMed ID: 31116052
[No Abstract] [Full Text] [Related]
13. Disease activity of lung cancer at the time of acute exacerbation of interstitial lung disease during cytotoxic chemotherapy.
Sekine A; Matama G; Hagiwara E; Tabata E; Ikeda S; Oda T; Okuda R; Kitamura H; Baba T; Satoh H; Misumi T; Komatsu S; Iwasawa T; Ogura T
Thorac Cancer; 2022 Sep; 13(17):2443-2449. PubMed ID: 35840339
[TBL] [Abstract][Full Text] [Related]
14. Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.
Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
Thorac Cancer; 2021 Jun; 12(11):1681-1689. PubMed ID: 33939332
[TBL] [Abstract][Full Text] [Related]
15. Effect of collagen vascular disease-associated interstitial lung disease on the outcomes of lung cancer surgery.
Maeda H; Kanzaki M; Sakamoto K; Isaka T; Oyama K; Murasugi M; Onuki T
Surg Today; 2017 Sep; 47(9):1072-1079. PubMed ID: 28247107
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study.
Koda K; Enomoto Y; Aoshima Y; Amano Y; Kato S; Hasegawa H; Matsui T; Yokomura K; Mochizuki E; Matsuura S; Koshimizu N; Morita M; Kojima S; Watanabe A; Oyama Y; Ikeda M; Kusagaya H; Uto T; Sato J; Imokawa S; Kono M; Hashimoto D; Kamiya Y; Toyoshima M; Asada K; Morita M; Mikamo M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suda T
Ther Adv Chronic Dis; 2022; 13():20406223221108395. PubMed ID: 35782342
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of lower-lobe interstitial lung disease on high-resolution computed tomography in patients with idiopathic pleuroparenchymal fibroelastosis.
Kono M; Fujita Y; Takeda K; Miyashita K; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Enomoto N; Nakamura Y; Suda T; Nakamura H
Respir Med; 2019; 154():122-126. PubMed ID: 31238182
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K
BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113
[TBL] [Abstract][Full Text] [Related]
19. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
[TBL] [Abstract][Full Text] [Related]
20. Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Suda T
Clin Med Insights Circ Respir Pulm Med; 2015; 9(Suppl 1):155-62. PubMed ID: 27279757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
